The total trade value of SCO Member States has increased nearly 100 times over the past 20 years

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Ecosia Shifts AI Search Toward Open-Weight Models, Including Chinese LLMs

Ecosia, the Berlin-based search engine, is shifting more of its AI services toward open-weight models, including Alibaba’s Qwen, Z.ai’s GLM and Moonshot AI’s Kimi, through German AI platform Melious. Founder and CEO Christian Kroll told Politico that the change had roughly halved costs while improving quality and performance. The move shows how Chinese-developed models are entering Western products through European hosting and infrastructure.

Unpacking China | Key Chinese Firms to Watch This Week （4/10/2026-10/10/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Midea Completes Controlling Acquisition of Italian Medical Imaging Firm Esaote

Midea Group (美的集团) completed its acquisition of a controlling stake in Italian medical imaging company Esaote S.p.A. (百胜医疗) on October 9, the companies said. Esaote will join Midea Healthcare while continuing to operate as an independent business headquartered in Genoa, with research and manufacturing facilities in Italy and the Netherlands.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.